BRISBANE, Calif., Feb. 10 /PRNewswire-FirstCall/ -- WHAT: VaxGen, Inc. President and CEO Lance K. Gordon, Ph.D., will present a company update and participate in the Focus Session entitled: Vaccines: What Is on The Horizon? at the BIO CEO & Investor Conference 2006 in New York City. (Logo: http://www.newscom.com/cgi-bin/prnh/19991112/VAXGENLOGO ) WHEN/ WHERE: Company Presentation: 11:00 a.m. ET, Wednesday, February 15, 2006 Focus Session: Vaccines: What Is on The Horizon?: 3:30 p.m. ET, Wednesday, February 15, 2006 Waldorf Astoria, New York City HOW: To listen to a live webcast of the presentations, go to Webcasts in the Investor Relations section of VaxGen’s web site at www.vaxgen.com and click on the presentation link for BIO CEO Company Presentation, and/or the Focus Session. About VaxGen
VaxGen, Inc. is a biopharmaceutical company engaged in the development, manufacture and commercialization of biologic products for the prevention and treatment of human infectious diseases, including anthrax, smallpox and Meningitis B. The company has been awarded an $877.5 million U.S. government contract to provide 75 million doses of its recombinant anthrax vaccine for civilian biodefense. Based in Brisbane, Calif., VaxGen operates a wholly owned manufacturing facility in California and owns 21% of Celltrion, Inc., a South Korean operation established to provide contract manufacturing to the global pharmaceutical industry. For more information, please visit the company’s web site at: http://www.vaxgen.com .
Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/19991112/VAXGENLOGOAP Archive: http://photoarchive.ap.orgPRN Photo Desk photodesk@prnewswire.comVaxGen, Inc.
CONTACT: Pat Beaupre Becker of VaxGen, Inc., +1-650-624-1041
Web site: http://www.vaxgen.com/
